✦ LIBER ✦

A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer : North Central Cancer Treatment Group Study N0326

✍ Scribed by Grace K. Dy; Shauna L. Hillman; Kendrith M. Rowland Jr; Julian R. Molina; Preston D. Steen; Donald B. Wender; Suresh Nair; Sumithra Mandrekar; Steven E. Schild; Alex A. Adjei

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 176 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25448

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of pemetrexed in combinat

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer

✍ Ralph G. Zinner; Frank V. Fossella; Gregory W. Gladish; Bonnie S. Glisson; Georg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

The possible advantage of hyperfractiona

The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma : Results of a North Central Cancer Treatment Group Phase III study

✍ James A. Bonner; William L. McGinnis; Phillip J. Stella; Robert F. Marschke Jr.; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

## BACKGROUND. A three-arm Phase III randomized trial was performed

A phase 2 study of cetuximab in combinat

A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer

✍ Edward S. Kim; Ann M. Mauer; William N. William Jr; Hai T. Tran; Diane Liu; Jack 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB 👁 2 views

A randomized phase II trial of amonafide

A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the north central cancer treatment group

✍ Dean H. Gesme Jr.; James R. Jett; Dennis D. Schreffler; John Q. Su; James A. Mai 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 376 KB 👁 2 views

Randomized phase 2 study of irinotecan p

Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer

✍ Ji-Youn Han; Dae Ho Lee; Jung Eun Song; Sung Young Lee; Hyae Young Kim; Heung Ta 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati